A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.
Masahito KotakaYoji SaitoTakeshi KatoHironaga SatakeAkitaka MakiyamaYasushi TsujiKatsunori ShinozakiToshiyoshi FujiwaraTsunekazu MizushimaYasushi HariharaNaoki NagataNaoto KuriharaMasahiko AndoGenichi KusakawaTakumi SakaiYugo UchidaMikihiro TakamotoSaki KimotoIchinosuke HyodoPublished in: Cancer chemotherapy and pharmacology (2020)
ART-123 showed a potential preventive effect against OIPN with good tolerability. A larger study with 1-day ART is warranted. NCT02792842, registration date: June 8, 2016.